Massachusetts Financial Services Co. MA Acquires 4,112 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Massachusetts Financial Services Co. MA boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 155,985 shares of the company’s stock after buying an additional 4,112 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Neurocrine Biosciences were worth $21,474,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in Neurocrine Biosciences by 1.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 336,536 shares of the company’s stock valued at $44,343,000 after acquiring an additional 5,907 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Neurocrine Biosciences by 3.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock valued at $333,000 after purchasing an additional 78 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Neurocrine Biosciences by 87.5% during the fourth quarter. Janney Montgomery Scott LLC now owns 8,637 shares of the company’s stock valued at $1,138,000 after buying an additional 4,030 shares during the last quarter. Norges Bank bought a new stake in Neurocrine Biosciences during the fourth quarter worth $35,731,000. Finally, BI Asset Management Fondsmaeglerselskab A S raised its position in Neurocrine Biosciences by 162.0% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 3,702 shares of the company’s stock valued at $488,000 after buying an additional 2,289 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Julie Cooke sold 10,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $140.19, for a total transaction of $1,401,900.00. Following the sale, the insider now directly owns 18,202 shares in the company, valued at $2,551,738.38. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Julie Cooke sold 10,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $140.19, for a total value of $1,401,900.00. Following the completion of the transaction, the insider now owns 18,202 shares in the company, valued at $2,551,738.38. The disclosure for this sale can be found here. Insiders sold a total of 71,798 shares of company stock worth $10,676,096 in the last quarter. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Trading Down 1.8 %

NBIX opened at $118.35 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $103.63 and a 12 month high of $157.98. The company has a market cap of $11.91 billion, a PE ratio of 32.60 and a beta of 0.37. The company has a 50 day moving average of $138.49 and a 200 day moving average of $138.14.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The company had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. During the same period in the previous year, the business earned $0.95 earnings per share. Neurocrine Biosciences’s revenue was up 30.4% on a year-over-year basis. Research analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. UBS Group lifted their price objective on shares of Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, August 29th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Guggenheim boosted their target price on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Finally, Royal Bank of Canada reduced their target price on Neurocrine Biosciences from $143.00 to $136.00 and set a “sector perform” rating for the company in a report on Thursday, August 29th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $162.20.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.